NOVASECTA - Key Persons
Adam works across operating models and strategic decision-making in biotech and pharmaceutical companies. Prior to Novasecta, he worked in a psychiatric clinic before completing an MSc, during which he investigated novel treatments for depression using fMRI data.
Andrew is a Partner at Novasecta and joined the team through the acquisition of Strategy in Life Sciences (SiLS), where he was the Founder and Managing Director. Andrew has gained consulting experience from working with a wide range of pharmaceutical and biotech companies on their critical strategy issues, which includes commercial and corporate strategy development, business plan development, merger and acquisition advice and portfolio development. Prior to establishing SiLS, Andrew was an Executive Director at AVOS Consulting where he helped to establish a European healthcare consulting practice. His previous consulting experience also includes positions at Charles River Associates, IMS Consulting and L.E.K. Consulting.
John is responsible for the development of the firm and the successful delivery of many of its client projects. He has helped pharmaceutical, biotech and medical technology companies of all sizes and geographies address their most complex strategic and cultural challenges across R&D, commercial and corporate development disciplines. Prior to founding Novasecta, John held Partner or Principal positions in three global consulting firms, Analysis Group, Strategic Decisions Group, and Deloitte Haskins & Sells. He has also been an executive board member of two start-up biotechs from the University of Cambridge.
Richard is a Partner at Novasecta. Richard has extensive experience across the Life Sciences sector working for and consulting to a wide range of companies on major strategic and transformational programs. Richard held senior positions at SmithKline Beecham and Bristol-Myers Squibb and for several years led PA Consulting's Life Sciences Practice globally. Richard has also consulting experience working with PwC and IQVIA.